EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism

Yirui He, Yunhe Li, Yayi Chen, Sha Liu, Jia Liu, Rui Wei, Jiapeng Zhang

Cellular Oncology · 2025

DOI: 10.1007/s13402-025-01117-x ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Yirui He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Department of Urology and Institute of Urology, Department of Pulmonary and Critical Care Medicine, West China Hospital, Si…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, STAT3 Transcription Factor, Disease Progression. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Eukaryotic translation regulators have emerged as pivotal modulators of cancer progression and immune evasion. However, their mechanistic contributions in hepatocellular carcinoma (HCC) remain poorly understood. EIF2B4, the δ-subunit of the eukaryotic initiation factor 2B (eIF2B) complex, has not been previously characterized in HCC.

Methods

EIF2B4 expression was analyzed using public datasets and validated in clinical HCC samples. Functional assays, including gain- and loss-of-function experiments, were performed to assess its impact on cell proliferation, apoptosis, migration, and the cell cycle. RNA immunoprecipitation (RIP), luciferase reporter assays, immunoblotting, and mutational rescue were employed to elucidate EIF2B4-mediated translational regulation of STAT3. In vivo mouse models and immune co-culture systems were used to investigate the role of EIF2B4 in antitumor immunity and response to anti-PD-1 therapy.

Results

EIF2B4 was significantly upregulated in HCC and associated with poor prognosis. EIF2B4 promoted oncogenic phenotypes, including proliferation, migration, and cell cycle progression, while suppressing apoptosis. Mechanistically, EIF2B4 enhanced STAT3 protein expression by directly binding its mRNA and facilitating translation without affecting mRNA levels. EIF2B4 interacted with the eIF2 complex and required GEF activity to promote STAT3 translation via the 5′ untranslated region (5′UTR). GEF-inactivating mutations abolished EIF2B4’s translational and tumor-promoting effects. In vivo, EIF2B4 impaired CD8 + T cell-mediated cytotoxicity, reduced immune infiltration, and diminished the efficacy of anti-PD-1 therapy. Conversely, EIF2B4 knockout restored antitumor immunity and sensitized tumors to immune checkpoint blockade.

Conclusions

EIF2B4 functions as a previously unrecognized translational regulator that promotes HCC progression and immune evasion by enhancing STAT3 translation through a GEF-dependent mechanism. These findings highlight EIF2B4 as a potential therapeutic target and biomarker to improve immunotherapy responsiveness in HCC. Clinical trial number Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsSTAT3 Transcription FactorDisease ProgressionProtein BiosynthesisEukaryotic Initiation Factor-2BImmune EvasionHumansAnimalsCell Line, TumorCell ProliferationMiceGene Expression Regulation, NeoplasticCell MovementApoptosisMaleFemale

Stichwörter der Autor:innen

EIF2B4Hepatocellular carcinomaSTAT3 signalingTranslational regulationTumor immune evasion

Substanzen

STAT3 Transcription FactorEukaryotic Initiation Factor-2BSTAT3 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Department of Urology and Institute of Urology, Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Thoracic and Cardiac Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Geriatrics, Sichuan Second Hospital of Traditional Chinese Medicine, Chengdu, China.
  • Department of Hematology, Department of Urology and Institute of Urology, Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China. jp_zhang@scu.edu.cn.

Zitieren

APA

He, Y., Li, Y., Chen, Y., Liu, S., Liu, J., Wei, R., & Zhang, J. (2025). EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism. Cellular Oncology. https://doi.org/10.1007/s13402-025-01117-x

Vancouver

He Y, Li Y, Chen Y, Liu S, Liu J, Wei R, et al. EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism. Cellular Oncology. 2025. doi:10.1007/s13402-025-01117-x

BibTeX
@article{He2025,
  author = {He, Yirui and Li, Yunhe and Chen, Yayi and Liu, Sha and Liu, Jia and Wei, Rui and Zhang, Jiapeng},
  title = {EIF2B4 promotes hepatocellular carcinoma progression and immune evasion by driving STAT3 translation via a GEF-dependent mechanism},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-025-01117-x}
}
Kostenlos starten →